CN109125357A - A kind of probiotics that treating intestinal irritable syndrome-caprophyl liquid complex liquid - Google Patents
A kind of probiotics that treating intestinal irritable syndrome-caprophyl liquid complex liquid Download PDFInfo
- Publication number
- CN109125357A CN109125357A CN201811272144.7A CN201811272144A CN109125357A CN 109125357 A CN109125357 A CN 109125357A CN 201811272144 A CN201811272144 A CN 201811272144A CN 109125357 A CN109125357 A CN 109125357A
- Authority
- CN
- China
- Prior art keywords
- caprophyl
- probiotics
- liquid
- prepared
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Abstract
The invention discloses the compounds of a kind of probiotics and caprophyl transplantation treatment intestinal irritable syndrome, comprising the following steps: (1) prepared by standard caprophyl liquid；(2) the prebiotic bacterium solution of compound is prepared；(3) probiotics-caprophyl liquid complex liquid is prepared.It is proved through clinical research, to the therapeutic effect of diarrhea irritable bowel syndrome, better than exclusive use probiotics or caprophyl transplanting.
Description
Technical field
The present invention relates to field of medical technology, more particularly, to a kind of probiotics-caprophyl for treating intestinal irritable syndrome
The preparation of liquid complex liquid.
Background technique
Caprophyl transplanting (fecal microbiota transplantation, FMT) at least starts from medical history of world
4th century of Christian era, but until just having obtained unprecedented fast development in recent years.2013, FMT was written into U.S. doctor for the first time
Guide is learned, for controlling for recurrent Clestridium difficile infection (clostridiumdifficile infection, CDI)
It treats.Meanwhile being at home and abroad used for the treatment of the outer disease of the enterals such as inflammatory bowel disease, irritable bowel syndrome, metabolic syndrome
Achieve good clinical efficacy.It is well known that probiotics plays an important role in terms of improving intestinal health, but it is not people
Endogenous flora in body enteron aisle needs to take for a long time competence exertion effect.This patent transplants caprophyl, and probiotics combines,
The speed for promoting Intestinal Mucosal Injury in Patients Undergoing flora to rebuild improves the clinical curative effect of caprophyl transplanting.
Summary of the invention
The purpose of the present invention is compound probiotics and caprophyl transplanting are used in combination, treated to improve the clinical of caprophyl transplanting
Effect.
To achieve the goals above, the present invention provide compound probiotics and caprophyl liquid mixed liquor the following steps are included:
(1) prepared by standard caprophyl liquid；
(2) the prebiotic bacterium solution of compound is prepared；
(3) probiotics-caprophyl liquid complex liquid preparation；
Wherein, the prebiotic bacterium solution of compound be formulated as being separately added into 200ml sterile saline Lactobacillus helveticus 0.1-1 ×
1010/ CFU, bifidobacterium longum 0.1-1 × 109/ CFU is uniformly mixed.
The concrete operations of above-mentioned steps (1) are as follows: qualified donor is screened, respectively aseptic collection excrement, after homogeneous processing, warp thread
It is centrifuged after cloth filtering, discards supernatant and obtain caprophyl mud sediment object.
The concrete operations of above-mentioned steps (3) are as follows: be uniformly mixed the prebiotic bacterium solution of 200ml compound and caprophyl mud sediment object.
Compared with prior art, the invention has the benefit that
(1) probiotics and caprophyl are transplanted use in conjunction by the present invention, and Intestinal Mucosal Injury in Patients Undergoing flora can be promoted to rebuild faster, thus
Improve clinical efficacy.
Specific embodiment
Below in conjunction with the specific embodiment preferred embodiment that the present invention will be described in more detail.
Embodiment 1
Probiotics and the preparation of caprophyl liquid complex liquid, comprising the following steps:
(1) prepared by standard caprophyl liquid: screening 1 people of qualified donor, aseptic collection excrement 50g, after homogeneous processing, through gauze mistake
It is centrifuged after filter, discards supernatant and obtain caprophyl mud sediment object.
(2) the prebiotic bacterium solution of compound is prepared: being measured 200ml sterile saline as in sterile beaker, is separately added into Switzerland
Lactobacillus 1 × 1010/ CFU, bifidobacterium longum 0.5 × 109/ CFU is uniformly mixed.
(3) probiotics-caprophyl liquid complex liquid is prepared: the prebiotic bacterium solution of 200ml compound and caprophyl mud sediment object being mixed equal
It is even
The Therapy study of the probiotics of the present invention of embodiment 2 and caprophyl liquid complex liquid to diarrhea irritable bowel syndrome
(1) patient screening: the patient of the compound II of the Rome IBS in 1999, the age 20-60 years old, men and women was unlimited, did not connect in two weeks
By Tiny ecosystem and caprophyl transplantation treatment.All patients sign informed consent form, share 90 patient selections.Wherein receive caprophyl
Transplantation treatment, probiotics agents treatment and probiotics-caprophyl transplant combination therapy each 30.
(2) therapeutic scheme: each patient of caprophyl transplantation treatment group receives the standard caprophyl liquid for being equivalent to 50g excrement, through tying
Colonoscopy is delivered to colon, and treatment is primary；The each patient of probiotics agents treatment group receives to contain Lactobacillus helveticus 1 × 1010/ CFU, it is long double
Discrimination bacillus 0.5 × 109The capsule of/CFU one, daily three, total 14d；Probiotics-caprophyl transplanting combination therapy group is each through tying
The standard caprophyl liquid that colonoscopy is equivalent to 50g excrement to colon conveying is primary, while taking orally and containing Lactobacillus helveticus 1 × 1010/ CFU,
Bifidobacterium longum 0.5 × 109The capsule of/CFU one, daily three, total 14d.
(3) it curative effect evaluation: records respectively before and after treatment and quantifies patient clinical symptom (table 1), symptom general comment is divided into items
The sum of scoring.Stool routine examination inspection is carried out, and is graded by Bristol.
Every clinical symptoms improvement rate is calculated by following curative effect standard, calculates total improvement rate by symptom judgment criteria overall score.
Cure: every symptom completely disappears；Effective: every symptom is substantially reduced (to reduce > before symptom score is relatively treated after treatment
50%), >=2 grades of stool scoring decline；Effective: every symptom slightly mitigates (before symptom score is relatively treated after treatment
Reduce 20%~50%), stool scoring 1 grade of decline；Invalid: (treatment after comment without substantially reduced by symptom for every symptom
Divide and reduce < 20% before relatively treating), stool grading system is without decline.
1 IBS Symptoms index of table
Unnatural proportions: frequency of abnormity/defecation frequency
(4) therapeutic effect
Pretherapy and post-treatment IBS symptom score compares: after the transplanting of caprophyl transplantation group per rectum mirror row caprophyl is primary, patient's items disease
Shape scoring is remarkably decreased, and each symptom effective percentage rises to 86.1% from 70.2%, and symptom overall score drops to 4.49 from 9.29；Benefit
After 14d is treated, patient's items symptom score is remarkably decreased raw bacterium group, and each symptom effective percentage rises to 79.1% from 71.4%,
Symptom overall score drops to 5.16 from 9.18；Probiotics-caprophyl transplanting combination therapy group is through a colon caprophyl treatment and 14d mouthfuls
After taking probiotics agents treatment, patient's items symptom score is remarkably decreased, and each symptom effective percentage rises to 93.7% from 73.5%, symptom
Overall score drops to 1.26 (see Table 2 for details) from 9.05, and difference is extremely significant between each group.Therapeutic effect is followed successively by probiotics-caprophyl
Complex group > caprophyl transplantation group > probiotic group.
The pretherapy and post-treatment IBS symptom score of table 2
Claims (2)
1. a kind of probiotics for treating intestinal irritable syndrome-caprophyl liquid complex liquid, it is characterised in that including following components: standard excrement
Bacterium solution and the prebiotic bacterium solution of compound, wherein the prebiotic bacterium solution of compound is formulated as being separately added into Switzerland's cream in 200ml sterile saline
Bacillus 0.1-1 × 1010/ CFU, bifidobacterium longum 0.1-1 × 109/ CFU is uniformly mixed.
2. a kind of probiotics for treating intestinal irritable syndrome-caprophyl liquid complex liquid according to claim 1, it is characterised in that
The following steps are included:
(1) prepared by standard caprophyl liquid；
(2) the prebiotic bacterium solution of compound is prepared；
(3) probiotics-caprophyl liquid complex liquid preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811272144.7A CN109125357A (en) | 2018-10-24 | 2018-10-24 | A kind of probiotics that treating intestinal irritable syndrome-caprophyl liquid complex liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811272144.7A CN109125357A (en) | 2018-10-24 | 2018-10-24 | A kind of probiotics that treating intestinal irritable syndrome-caprophyl liquid complex liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109125357A true CN109125357A (en) | 2019-01-04 |
Family
ID=64806386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811272144.7A Withdrawn CN109125357A (en) | 2018-10-24 | 2018-10-24 | A kind of probiotics that treating intestinal irritable syndrome-caprophyl liquid complex liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109125357A (en) |
Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060228448A1 (en) * | 2005-04-11 | 2006-10-12 | The Iams Company | Pet food compositions comprising two components |
| CN101575582A (en) * | 2008-05-08 | 2009-11-11 | 景岳生物科技股份有限公司 | Lactobacillus separation strains with anti-inflammatory activity and application thereof |
| CN101606952A (en) * | 2008-06-17 | 2009-12-23 | 上海交通大学医学院附属第三人民医院 | The application of Bifidobacterium lactis in the prevention urinary system calculus |
| CN101715816A (en) * | 2009-11-18 | 2010-06-02 | 内蒙古伊利实业集团股份有限公司 | Fermented milk containing probiotics, production method thereof and application thereof |
| CN101897729A (en) * | 2009-05-31 | 2010-12-01 | 金士力佳友(天津)有限公司 | Probiotic composition and preparation thereof |
| CN102300472A (en) * | 2009-01-06 | 2011-12-28 | 玫瑰花蕾公司 | Symbiotic composition, and method for manufacturing same |
| CN102596980A (en) * | 2009-08-26 | 2012-07-18 | Rna公司 | Lipoteichoic acid-derived glycolipids, and compositions comprising same |
| CN102613458A (en) * | 2012-04-16 | 2012-08-01 | 广东仙乐制药有限公司 | Probiotics soft capsule and preparation method thereof |
| CN104068393A (en) * | 2014-06-05 | 2014-10-01 | 胡安然 | Diet for relieving kidney stones |
| CN104922158A (en) * | 2015-06-05 | 2015-09-23 | 中国人民解放军第三军医大学第三附属医院 | Fecal microbiota capsule, as well as preparation method and application thereof |
| CN105820954A (en) * | 2016-05-24 | 2016-08-03 | 济南万泉生物技术有限公司 | Excrement flora in-vitro culture method and culture medium |
| US9408880B2 (en) * | 2013-12-20 | 2016-08-09 | Katherine Rose Kovarik | Method and system for prevention and treatment of allergic and inflammatory diseases |
| CN106954847A (en) * | 2017-03-30 | 2017-07-18 | 广州能靓生物技术有限公司 | Ferment probiotic composition with function of relaxing bowel, using and process preparation |
| CN107513515A (en) * | 2017-10-20 | 2017-12-26 | 南京益恒寿生命科技有限公司 | A kind of caprophyl transplantation treatment Plays caprophyl liquid preparing process |
| CN107574134A (en) * | 2017-10-20 | 2018-01-12 | 南京益恒寿生命科技有限公司 | A kind of caprophyl transplantation treatment Plays caprophyl lyophiled powder preparing technique |
| CN107874251A (en) * | 2017-11-14 | 2018-04-06 | 广东健来福云健康科技股份有限公司 | A kind of eight delicacies probiotic composition with strengthening the spleen and stomach benefit function of intestinal canal |
| CN108004189A (en) * | 2018-01-18 | 2018-05-08 | 北京科拓恒通生物技术股份有限公司 | A kind of compound probiotic lactic acid bacteria powder and preparation method and application |
| CN108567799A (en) * | 2018-08-01 | 2018-09-25 | 中国人民解放军总医院 | A kind of full caprophyl complex capsule and its preparation method and application |
| CN110169983A (en) * | 2019-05-28 | 2019-08-27 | 北京科拓恒通生物技术股份有限公司 | A kind of compound probiotic lactic acid bacteria powder and application thereof for treating irritable bowel syndrome |
| US20200063115A1 (en) * | 2017-03-15 | 2020-02-27 | Dupont Nutrition Biosciences Aps | Methods of using an archaeal serine protease |
| CN110913879A (en) * | 2017-06-02 | 2020-03-24 | 奥塔哥大学 | Use of lactic acid bacteria for treating or preventing at least one of postpartum depression and postpartum anxiety |
| US10695384B2 (en) * | 2011-02-18 | 2020-06-30 | Dupont Nutrition Biosciences Aps | Feed additive composition |
-
2018
- 2018-10-24 CN CN201811272144.7A patent/CN109125357A/en not_active Withdrawn
Patent Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060228448A1 (en) * | 2005-04-11 | 2006-10-12 | The Iams Company | Pet food compositions comprising two components |
| CN101575582A (en) * | 2008-05-08 | 2009-11-11 | 景岳生物科技股份有限公司 | Lactobacillus separation strains with anti-inflammatory activity and application thereof |
| CN101606952A (en) * | 2008-06-17 | 2009-12-23 | 上海交通大学医学院附属第三人民医院 | The application of Bifidobacterium lactis in the prevention urinary system calculus |
| CN102300472A (en) * | 2009-01-06 | 2011-12-28 | 玫瑰花蕾公司 | Symbiotic composition, and method for manufacturing same |
| CN101897729A (en) * | 2009-05-31 | 2010-12-01 | 金士力佳友(天津)有限公司 | Probiotic composition and preparation thereof |
| CN102596980A (en) * | 2009-08-26 | 2012-07-18 | Rna公司 | Lipoteichoic acid-derived glycolipids, and compositions comprising same |
| CN101715816A (en) * | 2009-11-18 | 2010-06-02 | 内蒙古伊利实业集团股份有限公司 | Fermented milk containing probiotics, production method thereof and application thereof |
| US10695384B2 (en) * | 2011-02-18 | 2020-06-30 | Dupont Nutrition Biosciences Aps | Feed additive composition |
| CN102613458A (en) * | 2012-04-16 | 2012-08-01 | 广东仙乐制药有限公司 | Probiotics soft capsule and preparation method thereof |
| US9408880B2 (en) * | 2013-12-20 | 2016-08-09 | Katherine Rose Kovarik | Method and system for prevention and treatment of allergic and inflammatory diseases |
| CN104068393A (en) * | 2014-06-05 | 2014-10-01 | 胡安然 | Diet for relieving kidney stones |
| CN104922158A (en) * | 2015-06-05 | 2015-09-23 | 中国人民解放军第三军医大学第三附属医院 | Fecal microbiota capsule, as well as preparation method and application thereof |
| CN105820954A (en) * | 2016-05-24 | 2016-08-03 | 济南万泉生物技术有限公司 | Excrement flora in-vitro culture method and culture medium |
| US20200063115A1 (en) * | 2017-03-15 | 2020-02-27 | Dupont Nutrition Biosciences Aps | Methods of using an archaeal serine protease |
| CN106954847A (en) * | 2017-03-30 | 2017-07-18 | 广州能靓生物技术有限公司 | Ferment probiotic composition with function of relaxing bowel, using and process preparation |
| CN110913879A (en) * | 2017-06-02 | 2020-03-24 | 奥塔哥大学 | Use of lactic acid bacteria for treating or preventing at least one of postpartum depression and postpartum anxiety |
| CN107513515A (en) * | 2017-10-20 | 2017-12-26 | 南京益恒寿生命科技有限公司 | A kind of caprophyl transplantation treatment Plays caprophyl liquid preparing process |
| CN107574134A (en) * | 2017-10-20 | 2018-01-12 | 南京益恒寿生命科技有限公司 | A kind of caprophyl transplantation treatment Plays caprophyl lyophiled powder preparing technique |
| CN107874251A (en) * | 2017-11-14 | 2018-04-06 | 广东健来福云健康科技股份有限公司 | A kind of eight delicacies probiotic composition with strengthening the spleen and stomach benefit function of intestinal canal |
| CN108004189A (en) * | 2018-01-18 | 2018-05-08 | 北京科拓恒通生物技术股份有限公司 | A kind of compound probiotic lactic acid bacteria powder and preparation method and application |
| CN108567799A (en) * | 2018-08-01 | 2018-09-25 | 中国人民解放军总医院 | A kind of full caprophyl complex capsule and its preparation method and application |
| CN110169983A (en) * | 2019-05-28 | 2019-08-27 | 北京科拓恒通生物技术股份有限公司 | A kind of compound probiotic lactic acid bacteria powder and application thereof for treating irritable bowel syndrome |
Non-Patent Citations (5)
| Title |
|---|
| MICHAËL MESSAOUDI等: ""Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers"", 《GUT MICROBES》 * |
| 周庭银等主编: "《临床微生物学诊断与图解》", 31 July 2001, 上海科学技术出版社 * |
| 周江伟等: ""粪菌移植方法学及其治疗肠易激综合征的研究进展"", 《实用医学杂志》 * |
| 国家工商行政管理总局和食品流通监督管理司编: "《流通环节食品安全监管工作指南》", 30 November 2011, 中国工商出版社 * |
| 陈洁: ""调节肠道微生态治疗肠易激综合征"", 《中国实用儿科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104922158B (en) | Caprophyl capsule and its preparation and application | |
| AU2017274416C1 (en) | Compositions and methods for treating inflammatory bowel diseases (IBDS) and other disorders | |
| KR102371868B1 (en) | Faecalibacterium prausnitzii and desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases | |
| CN110169983B (en) | Composite probiotic lactic acid bacteria powder for treating irritable bowel syndrome and application thereof | |
| Cruz et al. | Nocardiosis: Nocardial osteomyelitis and septicemia | |
| CN113249280B (en) | Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product | |
| Crompton et al. | Sarcoidosis associated with progressive muscular wasting and weakness | |
| Allerberger et al. | Urinary tract infection caused by nontyphoidal Salmonella: report of 30 cases | |
| CN102333534A (en) | Be used to treat the pharmaceutical composition that comprises proton pump inhibitor and prebiotics of gastric ulcer and duodenal ulcer | |
| Anscombe et al. | Caecal tuberculosis. | |
| US20210260136A1 (en) | Compositions and Methods for Treating Multiple Sclerosis and Related Disorders | |
| AU2018250206A1 (en) | Compositions and methods for treating parkinson's disease (PD) and related disorders | |
| Salvatorelli et al. | A new approach to the treatment of uncomplicated cystitis: results of a randomized placebo-controlled clinical trial | |
| JP2016069317A (en) | Inhibitors that inhibit progression of renal failure, prophylactics of renal failure, and inhibitors of indoxyl sulfate production | |
| CN109125357A (en) | A kind of probiotics that treating intestinal irritable syndrome-caprophyl liquid complex liquid | |
| Suri et al. | Serratia marcescens endocarditis. A report of a case involving Cross-Jones mitral valve prosthesis, with a review of the literature. | |
| Noel et al. | Pacemaker endocarditis caused by Propionibacterium acnes: a case report | |
| Dumic et al. | Early onset prosthetic joint infection and bacteremia due to Campylobacter fetus subspecies fetus | |
| US10092601B2 (en) | Compositions and methods for treating multiple sclerosis and related disorders | |
| Yekanath et al. | Miliary tuberculosis following ureteral catheterization | |
| CN117305188B (en) | Lactobacillus acidophilus RZKLa0701 capable of promoting bone growth of children and application thereof | |
| US20230043598A1 (en) | Capsule comprising a faecal composition | |
| CN115025120B (en) | Mesenchymal stem cell injection and application thereof | |
| Jiang et al. | Bacteriology of chronic sinusitis in relation to middle meatal secretion | |
| Zardi et al. | Shoulder Prosthetic Infection and Humerus Osteomyelitis From Cutibacterium Following Eden-Hybinette Procedure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190104 |
|
| WW01 | Invention patent application withdrawn after publication |